BriaCell Therapeutics Cash Flow Statement

Financials in millions USD. Fiscal year is August - July.

Millions USD. Fiscal year is Aug - Jul.

Fiscal Year	TTM	FY 2025	FY 2024	FY 2023	FY 2022	FY 2021
Period Ending	Jan '26 Jan 31, 2026	Jul '25 Jul 31, 2025	Jul '24 Jul 31, 2024	Jul '23 Jul 31, 2023	Jul '22 Jul 31, 2022	Jul '21 Jul 31, 2021
Net Income	-29.64	-26.31	-4.79	-20.3	-26.84	-13.82
Depreciation & Amortization	0.11	0.11	0.08	0.02	0.02	0.02
Loss (Gain) on Equity Investments	0.22	0.22	0.11	-	-	-
Stock-Based Compensation	0.81	0.78	1.8	2.19	3.07	1.97
Other Operating Activities	-1.09	-1.06	-28.38	-2.12	11.66	6.36
Change in Accounts Receivable	0.19	0.73	-0.73	0.01	-0.01	0.01
Change in Accounts Payable	-3.12	-3.89	6.05	0.66	0.25	-1.41
Change in Other Net Operating Assets	1.57	1.25	1.74	-4.2	-0.63	-0.89
Operating Cash Flow	-30.97	-28.17	-24.13	-23.74	-12.48	-7.75
Capital Expenditures	-	-	-0.46	-	-	-
Investment in Securities	-0.29	-7.65	-0.23	-	-	-
Investing Cash Flow	-0.29	-7.65	-0.68	-	-	-
Short-Term Debt Issued	-	-	-	-	-	0.22
Total Debt Issued	-	-	-	-	-	0.22
Short-Term Debt Repaid	-	-	-	-	-	-0.55
Total Debt Repaid	-	-	-	-	-	-0.55
Net Debt Issued (Repaid)	-	-	-	-	-	-0.33
Issuance of Common Stock	56.15	45.45	4.42	4	6.51	65.33
Repurchase of Common Stock	-	-	-	-0.05	-10.17	-
Other Financing Activities	-	-	-	-	-0.08	-
Financing Cash Flow	56.15	45.45	4.42	3.95	-3.74	65
Net Cash Flow	24.89	9.63	-20.39	-19.79	-16.23	57.25
Free Cash Flow	-30.97	-28.17	-24.58	-23.74	-12.48	-7.75
Free Cash Flow Per Share	-20.88	-66.58	-224.09	-228.03	-120.86	-257.22
Levered Free Cash Flow	-20.49	-18.89	-10.83	-15.87	-6.86	-5.83
Unlevered Free Cash Flow	-20.47	-18.87	-10.83	-15.87	-6.86	-5.78
Change in Working Capital	-1.36	-1.91	7.05	-3.53	-0.39	-2.28

Source: S&P Global Market Intelligence. Standard template. Financial Sources.